Flumatinib mesylate

Overview

Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl . Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC 50 values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-13905
• CAS No.: 895519-91-2
• Molecular Formula: C30H33F3N8O4S
• Molecular Weight: 658.69
• Purity: 99.80%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.08 mg/mL (3.16 mM); Clear solution
• Availability: In-stock

Source

Original product source